Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

Strong financial position supports clinical focus on advancing drug

candidates for treatment of lysosomal storage disorders

CRANBURY, N.J., May 13 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced financial results for the first quarter of 2008. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.34 per share ($0.28 per share on a non-GAAP basis) for the three months ended March 31, 2008. As of March 31, 2008, cash, cash equivalents, and marketable securities totaled $154.6 million.

"In the first quarter of 2008, we continued to advance our three lead clinical development programs. We also reported data from multiple clinical trials that add to the growing body of evidence demonstrating that treatment with our oral pharmacological chaperone drug candidates has the potential to benefit patients with Fabry, Gaucher and Pompe disease," said John F. Crowley, President and CEO of Amicus Therapeutics. "In the months ahead in 2008, we will be focused on advancing the global regulatory plan for Amigal Phase 3 development, evaluating opportunities for additional clinical studies in Gaucher and Pompe disease, as well as on identifying new therapeutic areas for applying our pharmacological chaperone technology platform."

Program Advancements

Fabry Disease:

Amigal(TM) (migalastat hydrochloride) is an investigational, oral therapeutic being developed for the treatment of Fabry disease. In March, clinical investiga
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... (PRWEB) August 18, 2014 Global HIV ... pharma report announced by Reportstack. The rate of HIV infection ... on a declining note at a positive rate across the ... from 2.3 million in 2005 to 1.5 in 2013, with ... cause for such drastic changes in the infection rates has ...
(Date:8/18/2014)... , Aug. 18, 2014 TNI BioTech, ... company pioneering the manufacturing and marketing of innovative therapies ... the Company is providing a second notice of TNI ... In making the announcement, Noreen Griffin , founder ... in advance for your participation in the Annual Meeting. ...
(Date:8/18/2014)... August 2014 Vier führende deutsche ... klinische Studie auf, in der eine Intraokularlinse ... das Sehvermögen bei allen Entfernungen verbessern, so ... keine Lese- oder Gleitsichtbrille mehr benötigen. Die ... FluidVision Accommodating Intraocular Lens (FluidVision akkomodative ...
(Date:8/16/2014)... a way to make atomic-force microscope probes 20 times ... as the weight of an individual virus. , The ... (ANU), hinges on using laser beams to cool a ... level of sensitivity achieved after cooling is accurate enough ... virus that is 100 billion times lighter than a ...
Breaking Biology Technology:Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4Laser makes microscopes way cooler 2
... , , , ... Healthcare today released new survey results revealing that 85 percent of ... concern. Yet, when asked about testing their children for allergies, ... options available. Furthermore, more than one-third were not familiar with the ...
... , London, July 20 There has been a ... and biotechnology space. While the economic downturn and related credit crunch ... M&A mania, which has including four mega M&As in the first ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , , "The ...
... , , COLUMBIA, Md., July 17 ... DHA, Martek Biosciences (Nasdaq: MATK ), announced today that it ... Food Chain and Animal Health (SCFCAH) of the European Union for additional ... , This is a significant action that will provide ...
Cached Biology Technology:American Mothers Seriously Concerned About Childhood Allergies, Siemens Survey Reveals 2American Mothers Seriously Concerned About Childhood Allergies, Siemens Survey Reveals 3American Mothers Seriously Concerned About Childhood Allergies, Siemens Survey Reveals 4American Mothers Seriously Concerned About Childhood Allergies, Siemens Survey Reveals 5Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities 2EU Committee Approves New Food Applications for Martek's life'sDHA(TM) 2EU Committee Approves New Food Applications for Martek's life'sDHA(TM) 3
(Date:8/19/2014)... and other science courses are increasingly being asked ... they have a new textbook to help them ... this month by Princeton Press and co-authored by ... Biological Synthesis (NIMBioS), teaches readers about basic mathematical ... explore and explain biological phenomena. , Suitable for ...
(Date:8/19/2014)... a glass of fizzy soda knows that bubbles can ... finding with wide industrial applications, Princeton researchers have demonstrated ... the liquid as well. , "It is well known ... surprised, and fascinated, to discover that when we covered ... oil droplets into the water," said Howard Stone, the ...
(Date:8/19/2014)... 19 August 2014: An engineer at the University of ... having a brain to communicate with the body. , ... L Mahadevan, has developed a mathematical model for earthworms ... how these soft bodied animals get around. , The ... pattern generator (CPG) which states that the central brain ...
Breaking Biology News(10 mins):New textbook introduces undergraduates to mathematics for the life sciences 2Bubbling down: Discovery suggests surprising uses for common bubbles 2Bubbling down: Discovery suggests surprising uses for common bubbles 3Secrets of how worms wriggle uncovered 2
... TXService learning involves the incorporation of community service into ... In the service learning model, students participate in ,real ... community. Researchers T.M. Waliczek and J.M. Zajicek reported on ... horticulture course in HortTechnology . The team found ...
... June 23, 2011 UT Southwestern Medical Center ... signaling pathway in Huntington,s disease, a finding that may ... slow the progression of degenerative nerve disorders. "Our ... disease treatment and possibly for other neurodegenerative diseases," said ...
... began working with legendary drug developer Paul Janssen, founder of ... an effort to create new and potent drugs to fight ... second anti-HIV drug that came from this collaboration., "For ... countless obstacles must be overcome," said Eddy Arnold, Board of ...
Cached Biology News:Service projects increase learning, social impact for undergrads 2Compound may provide drug therapy approach for Huntington's disease 2Rutgers laboratory helped to create new HIV drug 2Rutgers laboratory helped to create new HIV drug 3